Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content

Nephrology

Volumn 18, Issue 1, 2013, Pages 47-56

  Thallas Bonke, Vicki ^a,b   Coughlan, Melinda T ^a   Tan, Adeline L Y ^a,b   Harcourt, Brooke E ^a,c,d   Morgan, Philip E ^e,f   Davies, Michael J ^e   Bach, Leon A ^c   Cooper, Mark E ^a,b,c   Forbes, Josephine M ^a,b,c,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f University of Sydney   (Australia)

Author keywords

Advanced glycation end product; Diabetic nephropathy; Low AGE diet; RAGE deletion; Receptor for advanced glycation end product

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALBUMIN; COLLAGEN TYPE 4; GLYCOSYLATED HEMOGLOBIN; KIDNEY INJURY MOLECULE 1; PROTEIN KINASE C ALPHA; SCLEROPROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET THERAPY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE DELETION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; URINARY EXCRETION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DIET; DRUG EFFECT; GENETICS; KIDNEY; PHYSIOLOGY;

ANIMALS; DIET; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC;

EID: 84878383755     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01665.x     Document Type: Article

References (47)

1. Aparicio M, Chauveau P, Combe C. Low protein diets and outcome of renal patients. J. Nephrol. 2001; 14 (6): 433-9.
2. Davis NJ, Tomuta N, Schechter C et al. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. Diabetes Care. 2009; 32 (7): 1147-52.
3. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 2003; 14 (3): 728-31.
4. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. U.S.A. 1997; 94 (12): 6474-9.
5. Lee TC, Kimiagar M, Pintauro SJ, Chichester CO. Physiological and safety aspects of Maillard browning of foods. Prog. Food Nutr. Sci. 1981; 5 (1-6): 243-56.
6. O’Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr. 1989; 28 (3): 211-48.
7. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
8. Cerami C, Founds H, Nicholl I et al. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl Acad. Sci. U.S.A. 1997; 94 (25): 13915-20.
9. Harcourt BE, Sourris KC, Coughlan MT et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011; 80: 190-98.
10. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 1994; 14 (10): 1521-8.
11. Schmidt AM, Hasu M, Popov D et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl Acad. Sci. U.S.A. 1994; 91 (19): 8807-11.
12. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994; 269: 9889-97.
13. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 2001; 108: 261-8.
14. Myint KM, Yamamoto Y, Doi T et al. RAGE control of diabetic nephropathy in a mouse model: Effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006; 55 (9): 2510-22.
15. Sourris KC, Morley AL, Koitka A et al. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia. 2010; 53 (11): 2442-51.
16. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocininduced diabetic rat. Diabetes. 1991; 40 (10): 1328-34.
17. Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-9.
18. Forbes JM, Thallas V, Thomas MC et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003; 17 (12): 1762-4.
19. Henle T. AGEs in foods: Do they play a role in uremia? Kidney Int. Suppl. 2003; May (84): S145-7.
20. Liliensiek B, Weigand MA, Bierhaus A et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 2004; 113: 1641-50.
21. Zeng J, Davies MJ. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem. Res. Toxicol. 2005; 18 (8): 1232-41.
22. Forbes JM, Thallas-Bonke V, Cooper ME, Thomas MC. Advanced glycation: How are we progressing to combat this web of sugar anomalies in diabetic nephropathy. Curr. Pharm. Des. 2004; 10 (27): 3361-72.
23. Su Q, Coughlan MT, Thomas MC. HPLC-estimated creatinine clearance in rodents is superior to isotopic GFR (Abstract). J. Am. Soc. Nephrol. [Abstract]. 2007; 18: 165A.
24. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin. Chem. 1994; 40 (7 Pt 1): 1317-21.
25. Coughlan MT, Thallas-Bonke V, Pete J et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy? Endocrinology 2007; 148: 886-95.
26. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25 (5): 1111-15.
27. Thallas-Bonke V, Lindschau C, Rizkalla B et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53 (11): 2921-30.
28. Thallas-Bonke V, Thorpe SR, Coughlan MT et al. Inhibition of NADPH oxidase prevents advanced glycation end productmediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57: 460-69.
29. Thallas-Bonke V, Coughlan MT, Bach LA, Cooper ME, Forbes JM. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. Am. J. Nephrol. 2010; 32: 73-82.
30. Coughlan MT, Forbes JM. Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes. Am. J. Nephrol. 2011; 34: 9-17.
31. Coughlan MT, Thorburn DR, Penfold SA et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009; 20 (4): 742-52.
32. Vaidya VS, Ozer JS, Dieterle F et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 2010; 28 (5): 478-85.
33. Cai W, He JC, Zhu L et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: Association with increased AGER1 expression. Am. J. Pathol. 2007; 170: 1893-902.
34. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 2003; 162: 1123-37.
35. Tan AL, Sourris KC, Harcourt BE et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2010; 298: F763-70.
36. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 2002; 18 (3): 224-37.
37. Forbes JM, Soulis T, Thallas V et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-14.
38. Peppa M, Brem H, Cai W et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am. J. Nephrol. 2006; 26 (5): 430-36.
39. Watson AM, Gray SP, Jiaze L et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing rage activation in diabetic apolipoprotein E knockout mice. Diabetes 2012; 61 (8): 2105-13.
40. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 2007; 212: 209-17.
41. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol. 2004; 286: F552-63.
42. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999; 48 (6): 1308-15.
43. Cai W, He JC, Zhu L et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 2008; 173: 327-36.
44. Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002; 51 (7): 2082-9.
45. Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl Acad. Sci. U.S.A. 2002; 99 (24): 15596-601.
46. Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases: Not just in mammals. Biochimie. 2007; 89 (9): 1107-12.
47. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid. Redox Signal. 2006; 8 (9-10): 1597-607.